Resistell AG
- Category: Deeptech, Better Health and Human Capital, [Other]
Resistell AG is a Swiss diagnostics developer utilising the proprietary, 2 hours, growth independent, phenotypic Antibiotic Susceptibility Testing (AST) Platform. Resistell completed technology validation stage and is searching for an investment / strategic partnerships to industrialize high-throughput device and disposable.
Problem solved:
Speed of diagnostics for patients with blood stream infections.
Solution description:
Ultra rapid Antibiotic Susceptibility Testing platform based on assessment of vibration of living cells. We utilise MEMS sensors with optical read-out system to assess the vibrations patterns of bacterial cells.
Differentiation:
All other methods measure bacterial growth, which is too slow to provide targeted treatment on time (minimum 24 hours) . Our test is based of measurement of vibration of cells and thanks to this our time to result of 2 hours only. Our solution has a large clinical impact and will save many lives.
Targeted markets:
21000 hospitals around the world. Pharmaceutical companies developing new drugs. CROs. Estimated market size for diagnostics alone is >5B.
Unique Selling Proposition (USP) of your solution:
Clinically impactful ultra rapid time to result of 2 hours only => time to life saving targeted treatment.
Business model:
One off sales of instruments to hospitals.
40 years long daily supply of diagnostics consumables.
Expected Collaboration:
Investment, partnerships for industrialisation of our technology and commercialisation in all markets.